CN100437113C - Kit for detecting concentration ratio of phenacetin and acetaminophen in blood and application thereof - Google Patents
Kit for detecting concentration ratio of phenacetin and acetaminophen in blood and application thereof Download PDFInfo
- Publication number
- CN100437113C CN100437113C CNB200610043562XA CN200610043562A CN100437113C CN 100437113 C CN100437113 C CN 100437113C CN B200610043562X A CNB200610043562X A CN B200610043562XA CN 200610043562 A CN200610043562 A CN 200610043562A CN 100437113 C CN100437113 C CN 100437113C
- Authority
- CN
- China
- Prior art keywords
- kit
- phenacetin
- liver
- acetaminophen
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 title claims abstract description 62
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 229960003893 phenacetin Drugs 0.000 title claims abstract description 32
- 229960005489 paracetamol Drugs 0.000 title claims abstract description 24
- 210000004369 blood Anatomy 0.000 title claims abstract description 19
- 239000008280 blood Substances 0.000 title claims abstract description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims abstract description 12
- 239000007864 aqueous solution Substances 0.000 claims abstract description 10
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 6
- 239000011734 sodium Substances 0.000 claims abstract description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 claims abstract description 6
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims abstract description 6
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 2
- 230000003908 liver function Effects 0.000 abstract description 15
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 abstract 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 17
- 238000001514 detection method Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 6
- 208000019425 cirrhosis of liver Diseases 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 230000036983 biotransformation Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000005308 flint glass Substances 0.000 description 1
- WGXUDTHMEITUBO-YFKPBYRVSA-N glutaurine Chemical compound OC(=O)[C@@H](N)CCC(=O)NCCS(O)(=O)=O WGXUDTHMEITUBO-YFKPBYRVSA-N 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention discloses a kit for detecting the concentration ratio of phenacetin and acetaminophen in blood, which comprises a kit body and applying agent filled in the kit body, wherein the applying agent comprises hydrochloric acid with the volume percent of 20%, aqueous solution of 1, 2-naphthoquinone-4-sodium sulfonate with the quality and volume percent of 0.02%, aqueous solution of cetyl three-first-grade ammonium bromide with the quality and volume percent of 1%, aqueous solution of sodium carbonate with the quality volume percent of 8%, and aqueous solution of trichloroacetic acid with the volume percent of 10%. The present invention also discloses the application of the kit in evaluating liver function. The kit of the present invention has the characteristics of high detecting speed, simple operation and low cost.
Description
Technical field
The present invention relates to a kind of kit and application thereof, relate in particular to a kind of kit and application in liver function detects and estimates thereof that detects phenacetin and acetaminophen concentration ratio in the blood.Belong to technical field of medical detection.
Background technology
In China, chronic liver disease is common disease and frequently-occurring disease, and only hepatitis b virus carrier accounts for more than 10% of China's total population just up to people more than 100,000,000.1,000,000 neonates are arranged because mother and baby's vertical transmission may be infected hepatitis B every year.In addition, metabolic disorder, medicine, excessive drinking and autoimmune disease also are the common causes that causes that liver damages.Because chronic liver damages and mainly occurs in person between twenty and fifty, in case be transformed into cirrhosis, except that bringing out liver cancer, himself also is a kind of irreversible pathologic process, give society and family economical with cause great burden and misery mentally.Therefore, in liver function detects, accomplish that hepatopathy is early diagnosed, prevent from morning, early treatment is necessary.
At present, (mensuration such as γ-GT), lactic dehydrogenase is referred to as liver function test, and this is incorrect with glutamic-pyruvic transaminase (SGPT), glutamic-oxalacetic transaminease (SGOT), alkaline phosphatase-glutamyl transpeptidase clinically.As people (Postgrad Med 2003 such as Limd JR; That 79:307～312) points out is such, and these inspections are indexs that liver cell suffers damage, and can not reflect the function of liver.Liver function is meant: three big substance metabolism functions of the bio-transformation function of the function of detoxification of liver, liver, the excretory function of liver, liver and liver are at brephic hematopoiesis function.And the routine inspection relevant with these functions at present mainly contains three indexs, and promptly plasma albumin assay, serum bilirubin level are measured and prothrombin time.But in clinical position, often running into some patients like this, is the hepatitis carrier in early days, and the every inspection relevant with liver is all normal, but develops into cirrhosis or liver cancer later on.Some fatty liver, the drink patient of back chronic liver disease for a long time, the institutional framework of liver is obviously destroyed, but it is all normal to have the liver function experimental index now.In case accept operation on liver or interventional therapy, it is weak serious liver function often to occur, even dead.This illustrates that existing detection index sensitivity is low, and poor specificity can not satisfy clinical needs.Thereby correct evaluating liver function is the key of liver diseases early diagnosis, early prevention and early treatment.
Correct evaluating liver function is clinical both at home and abroad and the long-term emphasis of paying close attention to of element task person.The research in this field in recent years makes substantial progress, and finds that the outer metabolism of phenacetin liver is few, and is not induced by classical liver drug enzyme derivant sodium phenobarbital.Illustrate that it is the desirable target spot of evaluating liver function that the ethyl enzyme is removed in phenacetin oxygen position.Phenacetin is the specific substrate that the ethyl enzyme is removed in liver second ammonia ether oxygen position, and this enzyme is constitutive expression at liver.After the oral or intravenous injection, go under the ethyl enzymatic in phenacetin oxygen position, phenacetin is metabolised to acetaminophen.Measure phenacetin and acetaminophen ratio in the blood, can accurately reflect the bio-transformation function of liver.The phenacetin few side effects, bad reaction is little, and the minimum toxic dose of human body is desirable probe medicines of clinical trial greater than 5 grams.
The content of phenacetin and acetaminophen now more in the serum adopts exact instrument analytic approach (HPLC) to measure, though this method is accurate, and the precision height, the cost height, speed is slow, and poor practicability is difficult for promoting.Therefore, press for method and the kit that phenacetin and acetaminophen concentration ratio in a kind of not only easy but also accurate, practical detection blood can be arranged.
Summary of the invention
At the deficiencies in the prior art, the problem to be solved in the present invention provides a kind of kit and application in liver function detects and estimates thereof that detects phenacetin and acetaminophen concentration ratio in the blood.
Kit of the present invention can accurately be measured phenacetin and acetaminophen concentration ratio in the blood, and simple and efficient, easy to operate, cost is low, is suitable for the use of hospitals at different levels.
The kit of phenacetin and acetaminophen concentration ratio comprises box body in the detection blood of the present invention, is located at the application reagent in the box body; It is characterized in that: described application reagent is respectively: percent by volume is 20% hydrochloric acid, the quality percent by volume is 0.02%1, the aqueous solution of 2-naphthoquinones-4-sodium sulfonate, the quality percent by volume is the aqueous solution of 1% cetyl trimethyl ammonium bromide, the quality percent by volume is the aqueous solution of 8% sodium carbonate, and percent by volume is 10% trichloroacetic acid solution.
The application of above-mentioned kit in the evaluating liver function.
The using method of mentioned reagent box is as follows:
(1) the oral 1 gram phenacetin of patient, blood drawing after 2 hours, separation of serum is standby.
(2) get serum 1ml, add 10% trichloroacetic acid 1.5ml, carry out the deproteinized operation, centrifugal 15min under 3000 rev/mins of conditions isolates supernatant.
(3) get the 25ml volumetric flask and add above-mentioned 1ml supernatant, 0.25ml 20% hydrochloric acid, water-bath backflow 45min.
(4) be cooled to room temperature after, add 7.5ml 8% sodium carbonate, fully vibration adds 6ml 0.02%1,2-naphthoquinones-4-sodium sulfonate, 1ml 1% cetyl trimethyl ammonium bromide then successively.
(5) according to the principle of dual-wavelength spectrophotometry, measure absorbance at 491nm and 539nm wavelength, according to formula Δ A
1=0.000205C (Δ A
1Be the absorbance difference of 491nm and 539nm in the chromogenic reaction curve, the unit of C is ug/ml) measure the content of phenacetin, the content equation of measuring paracetamol is Δ A
2=0.000243C (Δ A
2Be the absorbance value difference of 470nm and 516nm in the chromogenic reaction curve, the unit of C is ug/ml).
(6) according to the concentration ratio of phenacetin and the acetaminophen index as the evaluating liver function, wherein: the ratio of the two is less than or equal to 1 in the healthy population, and dysfunction of liver person's ratio is greater than 1.
Kit advantage provided by the invention is:
(1) detection speed is fast.Remove the sample processing time in early stage, use liquid chromatography measure single component machine working time greater than 20 minutes, two kinds of compositions of this experiment measuring machine working time greater than 40 minutes, one day by the calculation of 8 hour working time, every day, test sample was less than 12 examples, and use this kit machine working time less than 2 minutes, can satisfy the needs of clinical a large amount of test sample.
(2) easy and simple to handle, cost is low.Liquid phase chromatography needs liquid chromatograph, and the instrument costliness requires height to operating personnel, and this kit agents useful for same is a general chemistry reagent, and used instrument also is the common spectrophotometer that medical institutions at different levels all have, and use cost is low, and is easy to utilize.
Embodiment
Embodiment 1
Single part of kit:
Preparation 10cm * 15cm * 10cm box body is provided with five slotted eyes that become dress to use reagent in box body, become to adorn a plastic bottle (volume 5ml) respectively, contains 10% trichloroacetic acid 2ml; Two flint glass F bottles (volume 2ml) contain 20% hydrochloric acid 1ml; No. three bottle plastic bottles (volume 10ml) contain 8% sodium carbonate 8ml; No. four Brown Glass Brown glass bottles and jars onlys (volume 10ml) contain 0.02%1,2-naphthoquinones-4-sodium sulfonate 7ml; No. five plastic bottles (volume 5ml) contain 1% cetyl trimethyl ammonium bromide 2ml; Promptly make the single part kit that detects phenacetin and acetaminophen concentration ratio in the blood.
Embodiment 2
Amount and reagent bottle volumetric quantity thereof according to embodiment 1 described application reagent, the scalable 10 person-portion kits that detect phenacetin and acetaminophen concentration ratio in the blood that are prepared into, hundred person-portion kits of phenacetin and acetaminophen concentration ratio in the detection blood, 300 person-portion kits of phenacetin and acetaminophen concentration ratio in the detection blood, 500 person-portion kits of phenacetin and acetaminophen concentration ratio in the detection blood.
Embodiment 3
Single part of kit of phenacetin and acetaminophen concentration ratio carries out the liver function detection of patient with liver cirrhosis in the Application Example 1 described detection blood:
(1) the oral 1 gram phenacetin of patient, blood drawing after 2 hours, separation of serum is standby.
(2) get serum 1ml, add 10% trichloroacetic acid 1.5ml, carry out the deproteinized operation, centrifugal 15min under 3000 rev/mins of conditions isolates supernatant.
(3) get the 25ml volumetric flask and add above-mentioned 1ml supernatant, 0.25ml 20% hydrochloric acid, water-bath backflow 45min.
(4) be cooled to room temperature after, add 7.5ml 8% sodium carbonate, fully vibration adds 6ml 0.02%1,2-naphthoquinones-4-sodium sulfonate, 1ml 1% cetyl trimethyl ammonium bromide then successively.
(5) according to the principle of dual-wavelength spectrophotometry, measure absorbance at 491nm and 539nm wavelength, according to formula Δ A
1=0.000205C (Δ A
1Be the absorbance difference of 491nm and 539nm in the chromogenic reaction curve, the unit of C is ug/ml) measure the content of phenacetin, the content equation of measuring paracetamol is Δ A
2=0.000243C (Δ A
2Be the absorbance value difference of 470nm and 516nm in the chromogenic reaction curve, the unit of C is ug/ml).
(6) according to the concentration ratio of phenacetin and the acetaminophen index as the evaluating liver function, dysfunction of liver person's ratio is greater than 1.
Detect to such an extent that the concentration ratio of described patient with liver cirrhosis phenacetin and acetaminophen is 4.6, diagnosable is dysfunction of liver.
Embodiment 4
Same quadrat method, the kit of Application Example 1 has been estimated the liver function of 20 routine normal persons and 12 routine patient with liver cirrhosis, found that the oral phenacetin of normal person after 2 hours, the ratio of phenacetin and acetaminophen is all less than 1 in its blood, and patient with liver cirrhosis is greater than 4.
Claims (1)
1. a kit that detects phenacetin and acetaminophen concentration ratio in the blood comprises box body, is located at the application reagent in the box body; It is characterized in that: described application reagent is respectively: percent by volume is 20% hydrochloric acid, the quality percent by volume is 0.02%1, the aqueous solution of 2-naphthoquinones-4-sodium sulfonate, the quality percent by volume is the aqueous solution of 1% cetyl trimethyl ammonium bromide, the quality percent by volume is the aqueous solution of 8% sodium carbonate, and percent by volume is 10% trichloroacetic acid solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200610043562XA CN100437113C (en) | 2006-04-11 | 2006-04-11 | Kit for detecting concentration ratio of phenacetin and acetaminophen in blood and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200610043562XA CN100437113C (en) | 2006-04-11 | 2006-04-11 | Kit for detecting concentration ratio of phenacetin and acetaminophen in blood and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1844923A CN1844923A (en) | 2006-10-11 |
| CN100437113C true CN100437113C (en) | 2008-11-26 |
Family
ID=37063866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200610043562XA Expired - Fee Related CN100437113C (en) | 2006-04-11 | 2006-04-11 | Kit for detecting concentration ratio of phenacetin and acetaminophen in blood and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100437113C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101349678B (en) * | 2007-06-12 | 2011-12-21 | 贺平 | Detection reagent kit for accurately evaluating liver function in early stage |
| CN101226175A (en) * | 2008-02-04 | 2008-07-23 | 李晓冬 | Application of acetophenetidin in preparation of medicaments for testing liver cancer high risk group |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0089857A1 (en) * | 1982-03-24 | 1983-09-28 | R.P. Scherer Corporation | Pharmaceutical compounds and process for the manufacture of same |
| CN1077288A (en) * | 1993-04-01 | 1993-10-13 | 壬京 | Simplify the immunological method and the kit of fast detecting hepatitis |
| CN1184255A (en) * | 1997-10-21 | 1998-06-10 | 曾真 | Detection method and reagent kit for subtype of hepatitis B virogene |
| WO2002002084A1 (en) * | 2000-06-29 | 2002-01-10 | Vincent Lenaerts | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
| WO2004038428A2 (en) * | 2002-10-25 | 2004-05-06 | Labopharm Inc. | Controlled-release compositions |
-
2006
- 2006-04-11 CN CNB200610043562XA patent/CN100437113C/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0089857A1 (en) * | 1982-03-24 | 1983-09-28 | R.P. Scherer Corporation | Pharmaceutical compounds and process for the manufacture of same |
| CN1077288A (en) * | 1993-04-01 | 1993-10-13 | 壬京 | Simplify the immunological method and the kit of fast detecting hepatitis |
| CN1184255A (en) * | 1997-10-21 | 1998-06-10 | 曾真 | Detection method and reagent kit for subtype of hepatitis B virogene |
| WO2002002084A1 (en) * | 2000-06-29 | 2002-01-10 | Vincent Lenaerts | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
| WO2004038428A2 (en) * | 2002-10-25 | 2004-05-06 | Labopharm Inc. | Controlled-release compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1844923A (en) | 2006-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Spitsin et al. | Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease | |
| Fung et al. | Pharmacokinetics of bisphenol A released from a dental sealant | |
| Kaplan et al. | Blood and urine levels of N, N-dimethyltryptamine following administration of psychoactive dosages to human subjects | |
| Jenne | Studies of human patterns of isoniazid metabolism using an intravenous fall-off technique with a chemical method | |
| Cooper et al. | Ion-pair extraction and high-speed liquid chromatography of cephalothin and deacetylcephalothin in human serum and urine | |
| CN101776675A (en) | Novel detection method of injection use compound amoxicillin sodium and clavulanate potassium | |
| Miotti et al. | The 30-minute aminopyrine breath test: optimization of sampling times after intravenous administration of 14C-aminopyrine | |
| CN100437113C (en) | Kit for detecting concentration ratio of phenacetin and acetaminophen in blood and application thereof | |
| Ratliff et al. | Serum propylthiouracil: determination by a direct colorimetric procedure | |
| Yokozawa et al. | Influence of green tea polyphenol in rats with arginine-induced renal failure | |
| Cass et al. | Effect of renal impairment on the pharmacokinetics of intravenous zanamivir | |
| Ekam et al. | Serum protein and enzyme levels in rats following administration of antioxidant vitamins during caffeinated and non-caffeinated paracetamol induced hepatotoxicity | |
| Feldman et al. | Salicylate absorption from a bismuth subsalicylate preparation | |
| Rampini et al. | Aromatic acids in urine of healthy infants, persistent hyperphenylalaninemia, and phenylketonuria, before and after phenylalanine load | |
| Bailey et al. | Methaqualone1 Overdose: Analytical Methodology, and the Significance of Serum Drug Concentrations | |
| Ellard | A sensitive urine-test method for monitoring the ingestion of isoniazid. | |
| JPH11225791A (en) | Rapid screening of state of cytochrome cyp2d6 | |
| Bukowskyj et al. | Theophylline clearance: lack of effect of influenza vaccination and ascorbic acid | |
| Peters et al. | Dapsone in saliva and plasma of man | |
| Klink et al. | Bioavailability and dissolution properties of two commercial digoxin tablets | |
| Verma et al. | Efficacy and safety of a Unani compound drug–Habb-e-Asgand in Waja ‘al-Mafāsil (Rheumatoid Arthritis) cases-A preliminary study | |
| Kirch et al. | Plasma homovanillic acid and tardive dyskinesia during neuroleptic maintenance and withdrawal | |
| Silas et al. | The disposition of debrisoquine in hypertensive patients | |
| US3577511A (en) | Process and compositions for differential diagnosis of the megaloblastic anemia syndromes | |
| Rey et al. | Influence of age on ortho-hydroxyphenylacetic acid excretion in phenylketonuria and its genetic variants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JI NAN CELL BIOLOGICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: WANG YUNSHAN Effective date: 20110421 Free format text: FORMER OWNER: CAO LIJUN |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250013 CENTRAL LABORATORY, JIN AN CENTRAL HOSPITAL, NO. 105, JIEFANG ROAD, JI NAN CITY, SHANDONG PROVINCE TO: 250101 B201, COMPREHENSIVE BUILDING, UNIVERSITY SCIENCE PARK, NO. 750, SHUNHUA ROAD, HIGH-TECH. ZONE, JI NAN CITY, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110421 Address after: 250101 Shandong city of Ji'nan province high tech Zone Shun Road No. 750 University Science Park building B201 Patentee after: Jinan Cell Bio-Technology Co., Ltd. Address before: 105 Central Laboratory of Ji'nan Central Hospital, Jiefang Road 250013, Ji'nan, Shandong, China Co-patentee before: Cao Lijun Patentee before: Wang Yunshan |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081126 Termination date: 20150411 |
|
| EXPY | Termination of patent right or utility model |